Current Diagnosis and Treatment of Painful Small Fiber Neuropathy

Farhad, Khosro

doi:10.1007/s11910-019-1020-1

Cited by 31 publications

(45 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are several evidence-based guidelines for management of painful neuropathy, but without individualising SFN [55]. Antidepressants (nortriptyline, amitriptyline, duloxetine, milnacipran, venlafaxine), anticonvulsants (gabapentin, pregabalin, lamotrigine, oxcarbazepine, carbamazepine, sodium valproate, lacosamide, topiramate), mexiletine, topical agents (capsaicin, lidocaine), opioids are frequently suggested, given their modest efficacy in large fibre neuropathy.…”

Section: Neurophysiological Test and Biopsy Can Help To Discriminate Between Fibromyalgia And Sfnmentioning

confidence: 99%

The challenge of differentiating fibromyalgia from small-fiber neuropathy in clinical practice

Bailly

2021

Joint Bone Spine

View full text Add to dashboard Cite

Section: Neurophysiological Test and Biopsy Can Help To Discriminate Between Fibromyalgia And Sfnmentioning

confidence: 99%

The challenge of differentiating fibromyalgia from small-fiber neuropathy in clinical practice

Bailly

2021

Joint Bone Spine

View full text Add to dashboard Cite

“…A definite claim is impossible because skin and/or mucosa biopsies are not usually done for this group of patients. In one recent review [47], SNF was associated with vitamin deficiency, gluten sensitivity and morbidity due to toxic agents. The author reported that autoantibodies to trisulfated heparin disaccharide and fibroblast growth factor receptor 3 were found in 20% of SFN patients.…”

Section: Sick Building Syndrome/dampness and Mold Hypersensitivity Syndrome Are Related To Other Chronic Illnesses And Autoimmunity In Pamentioning

confidence: 99%

The Roles of Autoimmunity and Biotoxicosis in Sick Building Syndrome as a “Starting Point” for Irreversible Dampness and Mold Hypersensitivity Syndrome

Tuuminen

2020

Antibodies

View full text Add to dashboard Cite

Background: The terminology of “sick building syndrome” (SBS), meaning that a person may feel sick in a certain building, but when leaving the building, the symptoms will reverse, is imprecise. Many different environmental hazards may cause the feeling of sickness, such as high indoor air velocity, elevated noise, low or high humidity, vapors or dust. The Aim: To describe SBS in connection with exposure to indoor air dampness microbiota (DM). Methods: A search through Medline/Pubmed. Results and Conclusions: Chronic course of SBS may be avoided. By contrast, persistent or cumulative exposure to DM may make SBS potentially life-threatening and lead to irreversible dampness and mold hypersensitivity syndrome (DMHS). The corner feature of DMHS is acquired by dysregulation of the immune system in the direction of hypersensitivities (types I–IV) and simultaneous deprivation of immunity that manifests as increased susceptibility to infections. DMHS is a systemic low-grade inflammation and a biotoxicosis. There is already some evidence that DMHS may be linked to autoimmunity. Autoantibodies towards, e.g., myelin basic protein, myelin-associated glycoprotein, ganglioside GM1, smooth muscle cells and antinuclear autoantibodies were reported in mold-related illness. DMHS is also a mitochondropathy and endocrinopathy. The association of autoimmunity with DMHS should be confirmed through cohort studies preferably using chip-based technology.

show abstract

“…In particular, several studies have documented the presence of small fibers neuropathy (SFN) in a significant percentage of patients with FM (5). The prevalence of SFN appears to be around 40-49% in FM patients (6,7). The presence of SFN can be demonstrated by histological examination performed on skin biopsy aimed at determining the intra-epidermal nerve fibers density (IENFD) or by examination of corneal innervation by confocal microscopy.…”

Section: Introductionmentioning

confidence: 99%

Sural Nerve Size in Fibromyalgia Syndrome: Study on Variables Associated With Cross-Sectional Area

et al. 2020

View full text Add to dashboard Cite

Current Diagnosis and Treatment of Painful Small Fiber Neuropathy

Cited by 31 publications

References 93 publications

The challenge of differentiating fibromyalgia from small-fiber neuropathy in clinical practice

The challenge of differentiating fibromyalgia from small-fiber neuropathy in clinical practice

The Roles of Autoimmunity and Biotoxicosis in Sick Building Syndrome as a “Starting Point” for Irreversible Dampness and Mold Hypersensitivity Syndrome

Sural Nerve Size in Fibromyalgia Syndrome: Study on Variables Associated With Cross-Sectional Area

Contact Info

Product

Resources

About